## A list of all abbreviations and terms appearing in this issue of *Therapy*.

AZL Activities of faily living Activities of All Physiology and Chronic Health Evaluation AUC <sub>p-100</sub> . All Physiology and Chronic Health Evaluation AUC <sub>p-100</sub> . Area under the plasma FU FVC Forced vital capacity NP2 FVC	6MWD	6-min walking distance	ER	Extended release	NEP	Nuclear export protein
AZE Adverse event (insection APACHE Acute Physiology and Chronic Health Evaluation Health Evaluation Second Concentration-time curve up to 168 h Great Concentration Concentration-time curve up to 168 h Great Concentration-time curve up to 168 h Great Concentration-time curve up to 168 h Great Concentration Concen						
APACHE Auther Physiology and Chronic Health Evaluation  APACHE Auther Physiology and Chronic Health Evaluation  ALV Authrysin deficiency FFMI Fathere mass index scond Second Sec						
APACHE Acute Physiology and Chronic Health Evaluation second seco			ESBL		NF-κB	Nuclear factor-κB
ATUC <sub>5, seasoner to the plasma process of th</sub>	APACHE	Acute Physiology and Chronic	FEV1		NHANES	National Health and Nutrition
AUC. 168 Area under the plasma (168 AUC. 168 AUC		Health Evaluation		second		Examination Survey
concentration-time curve up 16 168 h         FVC proced vital capacity of the sum of the			FFMI		NOS	•
168 h	AUC <sub>0-168h</sub>	Area under the plasma		•		
AUC <sub>bos</sub> Area under the plasma curve up to obstructive lung disease infinity         AUC spinificant concentration-time curve up to obstructive lung disease on infinity         NSAID Montainduction with plants of the plants		· · · · · · · · · · · · · · · · · · ·			Nrf2	
concentration-time curve up to infinity						
Infinity   HDAC   Histone deacety lase   HIF   Hypoxia-inducible factor   NSCLC   Non-small-cell lung carcinoma   12h   Every 12 h   Every 12 h   Oxacillin-resistant   13h	AUC <sub>0-∞</sub>		GOLD			3
BASL         Bronchoalveolar lavage         HIF         Hypoxia-inducible factor         NSCL         Non-small-cell lung carcinoma q12h         Non-small-cell lung valuable         Non-small-cell lung samp valuable         Non-small-cell lung valuable         Non-		•	LIDAG		NSAID	
BASC         Bronchoalveolar stem cell         i.v.         Intravenous         q12h         Every 12 h           BMI         Budy lated hydroxytoluene         IADL         Instrumental activities of daily living         ORSA         Oxacillia-resistant           BMI         Body mass index         IC         Instrumental activities of daily living         Peroxidilia resistant           BMDE         Body mass index, degree of airway obstruction, dyspnea and exercise capacity         IC         Instrumental activities of daily living         PaO, Arterial oxygen pressure           CAC         Collis-associated cancer         IKK         Inhibitor of NF-RB kinase         PPAP         Phospholiositide-3-kinase           CAP         Community-acquired pneumonia         IL         Interleukin         PRAP         Peroxisome proliferator           CB         Cannabinoid         III         Influenza-like-illness         PR         Pulmonary rehabilitation.           CCQ         Clinical CoPD Questionnaire         IIM         International normalized ratio         R         Randomized           CER         Cyclobenzaprine extended         IR         Immediate-release         R         Resistant           CGA         Comprehensive geriatric assessment         LABA         Long-actining jh-agonist         RS         Reduce vusceptibility	DAI				NISCLO	3
BHTI BMI BMI BMI BMI BMI BMI BOM yamass index of yamas index of yamas yama		_		• •		
BMIDE         Body mass index, degree of airway obstruction, dyspnea and exercise capacity         IC Inhaled corticosteroid         POPOPymerase         Staphylococcus aureus           CAC         Collisti-associated cancer         IKK         Inhaled corticosteroid         PDE         Phosphoinostitied-3-kinase           CAC         Community-acquired         IkK         Ishibitor of NF-IkB kinase         PPAR         Phosphoinostitied-3-kinase           CAP         Community-acquired         IkK         Ishibitor of NF-IkB kinase         PPAR         Phosphoinostitied-3-kinase           CAP         Community-acquired         IkK         Ishibitor of NF-IkB kinase         PPAR         Phosphoinostitied-3-kinase           CAP         Community-acquired         IkK         Ishibitor of NF-IkB kinase         PPAR         Phosphoinostitied-3-kinase           CB         Cannabinoid         ILI         Infreleukin         q.d.         Once daily           CEC         Clinical COPD Questionnaire         IM         Intramuscular         q.d.         Q.o.           CER         Cyclobenzaprine extended         IR         Intravenous         RN         Reactive introgen species           CFU         Colony-forming units         KPC         Klebsiella pneumoniae         RS         Reactive oxygen species						
BODDE airway obstruction, dyspnea and exercise capacityICInhaled corticosteroid Inspiratory capacity Intensive care unitPPolymerase PhosphodiesteraseCAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC 		, ,	IADL	· · · · · · · · · · · · · · · · · · ·	ONSA	
airway obstruction, dyspnea and exercise capacity         IC         Inspiratory capacity         PAO, Intensive care unit         Arterial oxygen pressure           CAC         Colitis-associated cancer         IKK         Inhibitor of NF-kB kinase         P3K         Phosphoinositide-3-kinase           CAP         Community-acquired pneumonia         IL         Influenza-like-illness         PRA         Peroxisome proliferator activated receptor.           CB         Cannabinoid         IL         Influenza-like-illness         PR         Pulmonary rehabilitation.           CCQ         Clinical COPD Questionnaire         IM         Intramuscular         q.d.         Once daily           CE         Clinical Iy evaluable         INR         Intramuscular         q.d.         Once daily           CER         Cyclobenzaprine extended         IR         Inmediate-release         R         Randomized           CEV         Colony-forming units         KPC         Klebsiella pneumoniae         RDS         Reactive nitrogen species           CEV         Colony-forming units         KPC         Klebsiella pneumoniae         RDS         Reactive oxygen species           CEV         Colony-forming units         KPC         Klebsiella pneumoniae         RDS         Reactive oxygen species           CEV			IC	3	Р	
CAC         Colitis-associated cancer         IKK         Inhibitor of NF-kB kinase         PDE         Phosphodiesterase           CAC         Colitis-associated cancer         IKK         Inhibitor of NF-kB kinase         PJRAR         Phosphoinositide-3-kinase           CAP         Community-acquired pneumonia         IL         Interleukin         PR         Peroxisome proliferator activated receptor.           CB         Canabinoid         ILI         Influenza-like-illness         PR         Pulmonary rehabilitation.           CCQ         Clinical COPD Questionnaire         IM         Intramuscular         q.d.         Once daily           CE         Clinically evaluable         INR         International normalized ratio         R         Randomized           CER         Cyclobenzaprine extended release         IR         Intravenous         RNS         Reactive introgen species           CFU         Colony-forming units         KPC         KPC         Kelbsiella pneumoniae         RDS         Reactive oxygen species           CGA         Comprehensive geriatric assessment         LABA         Long-actinig β <sub>1</sub> -agonist         RS         Reduced susceptibility           CI         Confidence interval         LAMA         Long-actinig β <sub>1</sub> -agonist         RS         Reduced susceptibility						
CAC         Colitis-associated cancer         IKK         Inhibitor of NF-kB kinase         P13K         Phosphoinositide-3-kinase           CAP         Community-acquired         I.K         Ix8-kinase         PPAR         Peroxisome proliferator           CB         Cannabinoid         ILI         Influenza-like-illness         PR         Pulmonary rehabilitation.           CCQ         Clinical COPD Questionnaire         IM         Intrawcular         q.d.         Once daily           CE         Clinically evaluable         INR         International normalized ratio         R         Randomized           CER         Cyclobenzaprine extended         IR         Immediate-release         R         Resistant           CFU         Colony-forming units         KPC         Klebsiella pneumoniae         RS         Reactive introgen species           CFU         Confidence interval         LABA         Long-acting inhaled muscarinic         RS         Reduced susceptibility           CI         Confidence interval         LAMA         Long-acting inhaled muscarinic         SC         Subcutaneous           CIA         Cyclobenzaprine immediate release         MAPK         Mitogen-activated protein         SCC         Squamous cell carcinoma           Cmax         Maximum plasma concentrati						
CAP         Community-acquired neumonia         IL Interleukin         PPAR activated receptor         Peroxisome proliferator activated receptor.           CB         Cannabinoid         ILI Influenza-like-illness         PR         Pulmonary rehabilitation.           CCQ         Clinical COPD Questionnaire         IM         Intrarauscular         q.d.         Once daily           CE         Clinically evaluable         INR         International normalized ratio         R         Randomized           CER         Cyclobenzaprine extended         IR         Immediate-release         R         Racistrant           CFU         Colony-forming units         KPC         Klebsiella pneumoniae         ROS         Reactive oxygen species           CFU         Comprehensive geriatric         carabpenemase         RR         Relative risk           CI         Confidence interval         LABA         Long-actining β-agonist         RS         Reduce dusceptibility           CI         Confidence interval         LABA         Long-actining β-agonist         S         Susceptible           CI         Confidence interval         LABA         Long-actining β-agonist         S         Susceptible           CI         Complicated intra-abdominal infection         MBABA         Muscarinic antagonist to a β-2	CAC		IKK	Inhibitor of NF-kB kinase	PI3K	
CBCannabinoidILIInfluenza-like-illnessPRPulmonary rehabilitation.CCQClinical (OPD QuestionnaireIMIntramuscularq.d.Once dailyCEClinically evaluableINRIntramuscularRR andomizedCERCyclobenzaprine extendedIRImmediate-releaseRR ResistantCFUColony-forming unitsKPCKlebsiella pneumoniaeROSReactive oxygen speciesCGAComprehensive geriatriccarbapenemaseRRRelative riskassessmentLABALong-acting β <sub>1</sub> -agonistRSReduced susceptibilityCIConfidence intervalLAMALong-acting inhaled muscarinic antagonistsSCSubcutaneousCIAIComplicated intra-abdominal infectionLDCTLow-radiation-dose CTSCCSquamous cell carcinomaCIRCyclobenzaprine immediate releaseMABAMuscarinic antagonist to a Muscarinic antagonist to a Muscarinic antagonist to a kinaseSCLCSmall-cell lung carcinomaCOPDChronic obstructive bronchitisMAPKMitogen-activated protein kinaseSGRQSaint George's Respiratory QuestionnaireCOYDCyclo-oxygenaseMCAMethylcholanthreneSTATSignal transducer and activator of transcriptionCOXCyclo-oxygenaseMCAMethylcholanthreneSVCSlow vital capacityCFICCaractive proteinMCMultidury resistanceSVCSlow vital capacityCFICCardiopulmonary exercise test	CA	Community-acquired	lκK	ΙκΒ-kinase	PPAR	
CCQClinically evaluableIMMIntramuscularq.d.Once dailyCEClinically evaluableINRInternational normalized ratioRRandomizedCERCyclobenzaprine extended releaseIVIntravenousRNSReactive nitrogen speciesCFUColony-forming unitsKPCKlebsiella pneumoniaeROSReactive nitrogen speciesCGAComprehensive geriatricLABALong-acting β <sub>2</sub> -agonistRSRelative riskCIConfidence intervalLABALong-acting inhaled muscarinic antagonistsSSusceptibleCIAIComplicated intra-abdominal infectionLDCTLOw-radiation-dose CTSCCSquamous cell carcinomaCIRCyclobenzaprine immediate releaseMABAMuscarinic antagonist to a particular deleaseSCCSquamous cell carcinomaCOMEMaximum plasma concentration releaseMAPAMuscarinic antagonist to a particular deleaseSCCSquamous cell carcinomaCOPDChronic obstructive bronchitisMAPAMuscarinic antagonist to a particular deleaseSCCSquamous cell carcinomaCOPDChronic obstructive pulmonaryMCMulticenterSMRSkeletal muscle relaxantsCOPDChronic obstructive pulmonaryMCMuthicose inhalerSTATSignal transducer and activator of transcriptionCPETCardiopulmonary exercise testMGRMultidose inhalerSVCSlow vital capacityCPETCreactive proteinMICMinimum inhibitoryt.i.d.Three-times daily </td <td>CAP</td> <td>Community-acquired pneumonia</td> <td>IL</td> <td>Interleukin</td> <td></td> <td>activated receptor.</td>	CAP	Community-acquired pneumonia	IL	Interleukin		activated receptor.
CE CR CVCIObenzaprine extended release CFUINR Cyclobenzaprine extended release IV COINT-forming units CGAINR Intravenous KPC Comprehensive geriatric assessment IABA COMPICIAL INTRACTION COMPICIAL INTRACTION CIAIN CIAIN CIAIN CIAIN COMPICIAL INTRACTION COMPICIAL INTRACTION CIAIN CIAIN COMPICIAL INTRACTION COMPICIAL INTRACTION CIAIN COMPICIAL INTRACTION CIAIN CIAIN COMPICIAL INTRACTION COMPICIAL INTRACTION CIAIN COMPICIAL INTRACTION COMPICIAL INTRACTION CONDITION OF TRACTION OF TRA	CB	Cannabinoid	ILI	Influenza-like-illness	PR	Pulmonary rehabilitation.
CER releaseCyclobenzaprine extended releaseIR IntravenousImmediate-release IntravenousRNS Reactive nitrogen speciesCFU COlony-forming units CGA COmprehensive geriatric assessmentLABA LABA LABA LONG-acting β <sub>1</sub> -agonist LABA LONG-acting β <sub>1</sub> -agonist Authority Infection CIAI COmplicated intra-abdominal infection release CCOB COBSTUCTIVE DEVICE COBSTUCTIVE DEVICE COBSTUCT COBSTUCTIVE DEVICE COBSTUCT COSSTUCT COBSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT COSSTUCT 	-					•
CFUColony-forming unitsKPCKlebsiella pneumoniaeRNSReactive nitrogen speciesCGAComprehensive geriatriccarbapenemaseRRRRRelative riskassessmentLABALong-acting β₂-agonistRSReduced susceptibilityCIConflicance intervalLAMALong-acting inhaled muscarinic antagonistsSSusceptibleCIAIComplicated intra-abdominal infectionLDCTLow-radiation-dose CTSCCSquamous cell carcinomaCIRCyclobenzaprine immediate releaseMABAMuscarinic antagonist to a β₂agonistSCLCSmall-cell lung carcinomaComaxMaximum plasma concentration COPDMAPKMitogen-activated protein kinaseSGRQSaint George's Respiratory QuestionnaireCOPDChronic obstructive bronchitisMCMulticenterSMRSkeletal muscle relaxantsCOYDCyclo-oxygenaseMCAMethylcholanthreneSTATSignal transducer and activatorCOXCyclo-oxygenaseMDIMultidose inhalerof transcriptionCFETCardiopulmonary exercise testMfMildridurg resistanceSVCSlow vital capacityCRPC-reactive proteinMICMinimum inhibitoryt.i.d.Three-times dailyCSSIComplicated skin and skinMMPMatrix-metalloproteinaseTAMTumor-associated macrophageCTGComplicated tissue growth factorMORCModified Medical ResearchTHT helper 1DBDouble-blindMPC <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
CFUColony-forming unitsKPCKlebsiella pneumoniae carbapenemase carbapenemase carbapenemase carbapenemase assessmentRRRelative risk Relative risk Reduced susceptibilityCIComprehensive geriatric assessmentLABA LABA LOng-acting β <sub>2</sub> -agonist antagonistsRSReduced susceptibilityCIComplicated intra-abdominal infectionLAMA LONG-acting inhaled muscarinic antagonistsSCSubcutaneousCIRCyclobenzaprine immediate releaseLDCT Maximum plasma concentration CORDMABA Muscarinic antagonist to a β <sub>2</sub> -agonistSCLC Scudamous cell carcinomaCORD COPD Chronic obstructive bronchitisMAPK Mitogen-activated protein kinaseMR Mitogen-activated protein kinaseSGRQ Saint George's Respiratory QuestionnaireCOXD COPD COPD COPD COPD CORTORIC obstructive pulmonary diseaseMC MID MUlticonterMultidose inhalerSMR MethylcholanthreneSMR Skeletal muscle relaxantsCOX CYCIO-oxygenase CPET CCTGI CCTGI CCTGI CORDIcated skin and skin structure infectionMID MID<	CER					
CGAComprehensive geriatric assessment CIcarbapenemase LABA Long-acting inhaled muscarinic antagonistRR Reduced susceptibilityCIAConfidence interval Confidence interval CIAILAMA LONG-acting inhaled muscarinic infection (CIR Cyclobenzaprine immediate releaseLDCT LOW-radiation-dose CT WABA Muscarinic antagonist to a β₂-agonistSCC SCC SQuamous cell carcinomaCIR Cyclobenzaprine immediate releaseMABA Muscarinic antagonist to a β₂-agonistSCLC SGRQ SGRQ SGRQ Saint George's Respiratory Questionnaire Of transcriptionCOX CYclo-oxygenase CPCT Cardiopulmonary exercise test Cardiopulmonary exercise test Mdr CrcI Creatinine clearance CrCI Creative protein CrCI Creative protein CSSI Complicated skin and skin structure infection MMR MMR MMR MMR MMR Matrix-metalloproteinase MMR Matrix-metalloproteinase MMR Matrix-metalloproteinase TAM Council Scale TLC Connective tissue growth factor Connective tissue growth factor Connective tissue growth factor Connective tissue growth factor Connectiv	CELL					• .
CIassessmentLABALong-acting β₂-agonistRSReduced susceptibilityCIConfidence intervalLAMALong-acting inhaled muscarinicSSusceptibleCIAIComplicated intra-abdominal infectionLDCTLow-radiation-dose CTSCCSquamous cell carcinomaCIRCyclobenzaprine immediate releaseMABA β₂-agonistMuscarinic antagonist to a β₂-agonistSCLCSmall-cell lung carcinomaCmaxMaximum plasma concentration COBMAPKMitogen-activated proteinSGRQ kinaseSaint George's Respiratory QuestionnaireCOPD Chronic obstructive pulmonary diseaseMC MCMulticenterSMR kinaseSkeletal muscle relaxantsCOX CYclo-oxygenaseMDI Multidose inhalerSTAT Multidury ersistanceSTAT Signal transducer and activatorCPET CArdiopulmonary exercise test CPCI Creatinine clearanceMIC Multidury ersistanceSVC Slow vital capacityCRP C-reactive proteinMIC ConcentrationMIC Multidury ersistanceSVC Slow vital capacityCSSSI Complicated skin and skin structure infectionMMP MARC Multidury ersistanceTAM Mitogen-activationTumor-associated macrophageCTG Computed tomography DLCOMMRC Modified Medical ResearchTH1 Thelper 1Thelper 1CTGF Connective tissue growth factor DB Double-blind for carbon monoxideMPC Multant preventionMCC Mutant preventionTLC Total lung capacityDLCO Diffusing capacity of the lung for car			KPC			
CIConfidence interval CIAILAMA Complicated intra-abdominal infectionLAMA LOCT LOW-radiation-dose CT Low-radiation-dose CTSC Subcutaneous SCL Squamous cell carcinomaCIR Cyclobenzaprine immediate release Cmax CMBA COB Chronic obstructive bronchitis COPD Chronic obstructive pulmonary diseaseMAPK Mitogen-activated protein KinaseSGRQ MulticenterSaint George's Respiratory QuestionnaireCOX CYclo-oxygenaseMDI Multidose inhalerSMR Mitogen-activated protein KinaseSMR OMETHIAL Signal transducer and activator of transcriptionCPET CFET CARDIO CREATION CARRELL CFCI CRP C-reactive protein STRUCTURE infectionMDI Multidose inhaler MIC MINIMUM minimum inhibitory concentration CORENTAL COMPACTURE infection Structure infection DUCOMIC MINIMUM minimum inhibitory concentration MMR MINIMUM minimum inhibitory concentrationTAM Tumor-associated macrophage Tage TigecyclineCTGF Computed tomography CTGF Connective tissue growth factor DB Double-blind DLCOMMRC MRC MINIMUM minimum minimum MRC MOdified Medical Research Council Scale Council Scale TILC Council Scale TILC Total lung capacityThe leper 1 Total lung capacityDLCO DIFfusing capacity of the lung for carbon monoxide DNA methyltransferase ECM EXTRACELUlar matrix FEXTRACELUlar matrix Group Group MRSA MSSA METHICIIII-resistant Staphylococcus aureus Staphylococcus aureus Medical Research Council Medical Research Council Mesenchymal stem cell Staphylococcus aureus Medical Research Council Medical Research Council M	CGA	-	LADA			
cIAIComplicated intra-abdominal infectionLDCT LDCTLow-radiation-dose CT Low-radiation-dose CTSCC SCC SQuamous cell carcinomaCIR Cyclobenzaprine immediate releaseMABA PagonistMuscarinic antagonist to a β₂-agonistSCLC Standard errorC <sub>max</sub> COB COPD Chronic obstructive bronchitis COPD COPD COPD COPD Chronic obstructive pulmonary diseaseMAPK MIC MCA MCA MCA MCA MCA MethylcholanthreneMIC MulticenterSMR Skeletal muscle relaxantsCOX CYclo-oxygenase CPET Creatinine clearance CTCI Creatinine clearanceMDI Multidrug resistance MIC Minimum inhibitory concentrationSVC Slow vital capacityCRP C-reactive protein CSSI Structure infection DB Double-blind DOuble-blind DICO Diffusing capacity of the lung for carbon monoxide DINAT DINAT DINAT EXTRACELILLAR TOUR DINAT DINAT EXTRACELILLAR TOUR DINAT DINAT EXTRACELILLAR TOUR DINAT EXTRACELILLAR TOUR MSA METHODIAL TOUR MSSA METHOLICHIA MISSA MESSA METHOLICHIA MISSA MESSA METHOLICHIA MISSA METHOLICHIA	CI					
Infection			LAIVIA			•
CIRCyclobenzaprine immediate releaseMABA β <sub>2</sub> -agonistMuscarinic antagonist to a β <sub>2</sub> -agonistSCLC SE Standard errorCmaxMaximum plasma concentration COB Chronic obstructive bronchitisMAPK Mitogen-activated protein kinaseSGRQ QuestionnaireCOPDChronic obstructive pulmonary diseaseMC MCAMulticenter McA MethylcholanthreneSMR Skeletal muscle relaxantsCOX Cyclo-oxygenaseMDI Multidose inhalerSTAT Of transcriptionSignal transducer and activator of transcriptionCPET Cardiopulmonary exercise test CPET Cardiopulmonary exercise testMIC MIC Minimum inhibitory concentration concentrationSVC Slow vital capacityCRP C-reactive proteinMIC Complicated skin and skin structure infectionMMR MIRM MIRM MIRM MIRM MIRM MIRM MIRM MIRM MIRM MIRM MIRM MIRM MOdified Medical Research Council Scale Concentration Concentration TIL Total lung capacityThe per 1 Till Total lung capacityCTGF Connective tissue growth factor DB Double-blind Double-blind Drose-limiting toxicity DNA EXTANCIBLE Transcription Toxicity DNA EXTANCIBLE Transcription MRSA Methicillin-resistant MSC Mesenchymal stem cellThe Median time to maximum plasma concentration Toxical lung capacity Toxical lung capacity Toxical lung capacity Toxical lung capacity Toxical lung capacityDLT Dose-limiting toxicity DNA EXTANCIBLE Transcription For carbon monoxide EXTANCIBLE Transcription MRSA Methicillin-resistant MSC Mesenchymal stem cell Mesenchymal stem c	CIAI	•	LDCT			
release	CIR					
Cmax COBMaximum plasma concentration Chronic obstructive bronchitisMAPK kinaseMitogen-activated protein kinaseSGRQ QuestionnaireSaint George's Respiratory QuestionnaireCOPChronic obstructive pulmonary diseaseMCA MethylcholanthreneMulticenter MCASMR MethylcholanthreneSKR Skeletal muscle relaxantsCOX COX<	Circ		1417 (157 (			3
COB Chronic obstructive bronchitis COPD Chronic obstructive pulmonary disease MCA Methylcholanthrene STAT Signal transducer and activator of transcription of t	C	Maximum plasma concentration	MAPK			
disease MCA Methylcholanthrene STAT Signal transducer and activator Of transcription Of Of transcription Of transcription Of transcription Of transcription Of transcription Of transcription Of Of transcription Of Of Of transcription Of	COB			_	•	
COX Cyclo-oxygenase MDI Multidose inhaler of transcription  CPET Cardiopulmonary exercise test Mdr Multidrug resistance SVC Slow vital capacity  CrCl Creatinine clearance MIC Minimum inhibitory t.i.d. Three-times daily  CRP C-reactive protein concentration t <sub>1/2</sub> Half-life  CSSSI Complicated skin and skin MMP Matrix-metalloproteinase TAM Tumor-associated macrophage structure infection MMR Mismatch repair TGC Tigecycline  CT Computed tomography MMRC Modified Medical Research  CTGF Connective tissue growth factor  DB Double-blind MPC Mutant prevention TLR Toll-like receptor  DLCO Diffusing capacity of the lung for carbon monoxide MRC Medical Research Council  DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD  ECM Extracellular matrix MSC Mesenchymal stem cell  EGFR EGF receptor Staphylococcus aureus Function with Tiotropium  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia	COPD	Chronic obstructive pulmonary	MC	Multicenter	SMR	Skeletal muscle relaxants
CPET Cardiopulmonary exercise test Mdr Multidrug resistance SVC Slow vital capacity  CrCl Creatinine clearance MIC Minimum inhibitory t.i.d. Three-times daily  CRP C-reactive protein concentration t <sub>1/2</sub> Half-life  CSSSI Complicated skin and skin MMP Matrix-metalloproteinase TAM Tumor-associated macrophage structure infection MMR Mismatch repair TGC Tigecycline  CT Computed tomography MMRC Modified Medical Research TH1 Thelper 1  CTGF Connective tissue growth factor Council Scale TLC Total lung capacity  DB Double-blind MPC Mutant prevention TLR Toll-like receptor  DLCO Diffusing capacity of the lung for carbon monoxide MRC Medical Research Council For carbon monoxide MRC Medical Research Council DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD Health  ECOG Eastern Cooperative Oncology MSI Microsatellite instability Group MSSA Methicillin-susceptible Group MSSA Methicillin-susceptible Staphylococcus aureus  EGFR EGF receptor Staphylococcus aureus Function with Tiotropium  NA Not applicable VAP Ventilator-associated pneumonia			MCA	Methylcholanthrene	STAT	Signal transducer and activator
CrCl Creatinine clearance MIC Minimum inhibitory t.i.d. Three-times daily  CRP C-reactive protein concentration t <sub>1/2</sub> Half-life  CSSSI Complicated skin and skin MMP Matrix-metalloproteinase structure infection MMR Mismatch repair TGC Tigecycline  CT Computed tomography MMRC Modified Medical Research TH1 T helper 1  CTGF Connective tissue growth factor  DB Double-blind MPC Mutant prevention TLR Toll-like receptor  DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD  ECM Eastern Cooperative Oncology MSI Microsatellite instability Group MSSA Methicillin-susceptible  EGFR EGF receptor  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia			MDI			
CRP C-reactive protein concentration t <sub>1/2</sub> Half-life  CSSSI Complicated skin and skin MMP Matrix-metalloproteinase structure infection MMR Mismatch repair TGC Tigecycline  CT Computed tomography MMRC Modified Medical Research TH1 Thelper 1  CTGF Connective tissue growth factor DB Double-blind MPC Mutant prevention TLR Toll-like receptor  DLCO Diffusing capacity of the lung for carbon monoxide MRC Medical Research Council  DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD ECM Extracellular matrix MSC Mesenchymal stem cell  ECOG Eastern Cooperative Oncology MSI Microsatellite instability UPLIFT Understanding Potential  Group MSSA Methicillin-susceptible Cong-term Improvements in Function with Tiotropium  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia						
CSSSI Complicated skin and skin MMP Matrix-metalloproteinase structure infection MMR Mismatch repair TGC Tigecycline  CT Computed tomography MMRC Modified Medical Research TH1 Thelper 1  CTGF Connective tissue growth factor DB Double-blind MPC Mutant prevention TLR Toll-like receptor  DLCO Diffusing capacity of the lung for carbon monoxide MRC Medical Research Council MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD ECM Extracellular matrix MSC Mesenchymal stem cell  ECOG Eastern Cooperative Oncology Group MSI Microsatellite instability Group MSSA Methicillin-susceptible Staphylococcus aureus  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia			MIC			
structure infection MMR Mismatch repair TGC Tigecycline  CT Computed tomography MMRC Modified Medical Research CTGF Connective tissue growth factor DB Double-blind MPC Mutant prevention TLR Toll-like receptor  DLCO Diffusing capacity of the lung for carbon monoxide MRC Medical Research Council  DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD  ECM Extracellular matrix MSC Mesenchymal stem cell  ECOG Eastern Cooperative Oncology Group MSSA Methicillin-susceptible Group MSSA Methicillin-susceptible  EGFR EGF receptor  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia						
CT Computed tomography MMRC Modified Medical Research TLC Total lung capacity  DB Double-blind MPC Mutant prevention TLR Toll-like receptor  DLCO Diffusing capacity of the lung for carbon monoxide MRC Medical Research Council  DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD  ECM Extracellular matrix MSC Mesenchymal stem cell  ECOG Eastern Cooperative Oncology Group MSSA Methicillin-susceptible Group MSSA Methicillin-susceptible Staphylococcus aureus  EGFR EGF receptor Staphylococcus aureus  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia	C2221			•		
CTGF Connective tissue growth factor DB Double-blind MPC Mutant prevention DLCO Diffusing capacity of the lung for carbon monoxide MRC Medical Research Council DLT Dose-limiting toxicity MRSA Methicillin-resistant DNAT DNA methyltransferase ECM Extracellular matrix MSC Mesenchymal stem cell ECOG Eastern Cooperative Oncology Group MSSA Methicillin-susceptible Group MSSA Methicillin-susceptible EGFR EGF receptor EMT Epithelial-mesenchymal NA Not applicable  Council Scale TLC Total lung capacity TORCH Toll-like receptor TNF Tumor necrosis factor TORCH Towards a Revolution in COPD Health UPLIFT Understanding Potential Long-term Improvements in Function with Tiotropium	CT					3 ,
DB Double-blind MPC Mutant prevention TLR Toll-like receptor  DLCO Diffusing capacity of the lung for carbon monoxide MRC Medical Research Council DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD ECM Extracellular matrix MSC Mesenchymal stem cell ECOG Eastern Cooperative Oncology Group MSI Microsatellite instability Group MSSA Methicillin-susceptible Staphylococcus aureus  EGFR EGF receptor Staphylococcus aureus  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia		, , ,	MINIKC			
DLCO Diffusing capacity of the lung for carbon monoxide MRC Medical Research Council plasma concentration  DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD  ECM Extracellular matrix MSC Mesenchymal stem cell Health  ECOG Eastern Cooperative Oncology Group MSI Microsatellite instability Group MSSA Methicillin-susceptible Staphylococcus aureus  EGFR EGF receptor Staphylococcus aureus  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia			MDC			
for carbon monoxide MRC Medical Research Council plasma concentration  DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD  ECM Extracellular matrix MSC Mesenchymal stem cell Health  ECOG Eastern Cooperative Oncology Group MSI Microsatellite instability Group MSSA Methicillin-susceptible Long-term Improvements in  EGFR EGF receptor Staphylococcus aureus Function with Tiotropium  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia			IVII C	•		
DLT Dose-limiting toxicity MRSA Methicillin-resistant TNF Tumor necrosis factor  DNMT DNA methyltransferase Staphylococcus aureus TORCH Towards a Revolution in COPD  ECM Extracellular matrix MSC Mesenchymal stem cell Health  ECOG Eastern Cooperative Oncology MSI Microsatellite instability UPLIFT Understanding Potential  Group MSSA Methicillin-susceptible Long-term Improvements in  EGFR EGF receptor Staphylococcus aureus  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia	DLCO		MRC		max	
DNMT DNA methyltransferase	DIT				TNF	•
ECM Extracellular matrix MSC Mesenchymal stem cell Health  ECOG Eastern Cooperative Oncology Group MSSA Methicillin-susceptible CGFR EGF receptor Staphylococcus aureus  EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia						
ECOG Eastern Cooperative Oncology Group MSI Microsatellite instability MSSA Methicillin-susceptible Long-term Improvements in Staphylococcus aureus Function with Tiotropium NA Not applicable VAP Ventilator-associated pneumonia	ECM		MSC	, ,		Health
Group MSSA Methicillin-susceptible Long-term Improvements in EGFR EGF receptor Staphylococcus aureus Function with Tiotropium EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia					UPLIFT	
EGFR EGF receptor Staphylococcus aureus Function with Tiotropium EMT Epithelial-mesenchymal NA Not applicable VAP Ventilator-associated pneumonia				•		
	EGFR	EGF receptor				Function with Tiotropium
transition NAI Neuraminidase inhibitor Vd Volume of distribution	EMT	Epithelial-mesenchymal			VAP	
		transition	NAI	Neuraminidase inhibitor	Vd	Volume of distribution